Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Arcturus Therapeutics Holdings
ARCT
Arcturus Therapeutics Holdings
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$42.00
55.9% undervalued
intrinsic discount
24 Aug
US$18.51
Loading
1Y
-13.7%
7D
3.4%
Author's Valuation
US$42.0
55.9% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$42.0
55.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-196m
296m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$17.9m
Earnings US$2.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
36.03%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$2.90m
Earnings '28
x
475.71x
PE Ratio '28
=
US$1.38b
Market Cap '28
US$1.38b
Market Cap '28
/
27.36m
No. shares '28
=
US$50.46
Share Price '28
US$50.46
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$41.45
Fair Value '25
